Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

University Hospital Center (CHU)

Status: Unknown

Conditions: Metastatic Melanoma

Study type: Observational

Funder types: Other

Identifiers

NCT05510466

RECHMPL22_0016

Details and patient eligibility

About

Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.

Enrollment: 18 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic melanoma BRAF mutated
• Initially treated by a doubled targeted therapy anti BRAF/anti MEK
• With an intra cerebral progression of the tumor
• Whom we add an check point inhibitor anti PD1, combined with the double targeted therapy
• between 01/2019 et 01/2022

Exclusion criteria

• Other condition